Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

Bullboard Posts

Post by dt_coreon Apr 22, 2011 3:31am

527 Views

Post# 18473962

BNN: HEM has 3 Bagger Potential

On BNN Market Call tonight, James Hodgins was talking about HEM again and this time provided some colour on share price potential. In his words he thinks its a 2 or 3 bagger from current levels. Anticipates revenue of $75mm to $80mm this year and $10mm in earnings next year.

Bullboard Posts

Canadian artificial intelligence ETFs